Clinical Trials Logo

Filter by:
NCT ID: NCT05884398 Recruiting - Clinical trials for Metastatic Castrate-sensitive Prostate Cancer

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

LIBERTAS
Start date: August 31, 2023
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level < 0.2 nanograms/millilitres (ng/mL) after 6 months of treatment with apalutamide and ADT combination therapy provides non-inferior radiographic progression-free survival (rPFS) and a reduced burden of hot flashes measured as 18-month percent change in severity adjusted hot flash score.

NCT ID: NCT05884372 Recruiting - Clinical trials for Osteoporosis in Postmenopausal Women

Comparison of Efficacy of Denosumab With Eldecalcitol or Native Vitamin D in Postmenopausal Women With Osteoporosis.

Start date: August 24, 2023
Phase: Phase 4
Study type: Interventional

Primary objective: To compare the bone mineral density (BMD) change under the treatment of denosumab with eldecalcitol or native vitamin D in postmenopausal women with osteoporosis on bone mineral density. Secondary objective: To compare the efficacy of denosumab with eldecalcitol or native vitamin D treatment in postmenopausal women with osteoporosis on bone turnover markers, serum PTH, serum calcium, serum phosphorus, muscle mass, muscle strength, body balance ability, and quality of life.

NCT ID: NCT05884255 Recruiting - Clinical trials for Advanced Gastroenteropancreatic Neuroendocrine Tumor

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Start date: July 6, 2023
Phase: Phase 3
Study type: Interventional

The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in Subjects With advanced gastrointestinal pancreatic neuroendocrine tumors.

NCT ID: NCT05884008 Recruiting - Clinical trials for Coronary Artery Disease

Risk Evaluation by COronary CTA and Artificial intelliGence Based fuNctIonal analyZing tEchniques - I

RECOGNIZE-I
Start date: May 1, 2023
Phase:
Study type: Observational

This study is a multicenter, retrospective imaging study. The study intends to retrospectively enroll patients with acute myocardial infarction who had received coronary CTA in a certain time-window before this event. All coronary CTA will be analyzed by anatomic, functional and radiomic analysis, assisted by artificial intelligence. The purpose of this study is to establish a coronary artery disease risk stratification system by coronary CTA.

NCT ID: NCT05883865 Recruiting - Clinical trials for Severe Hypertriglyceridemia During Pregnancy

Safety Study of Fenofibrate During Pregnancy

Start date: June 1, 2022
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety of fenofibrate in severe hypertriglyceridemia pregnant women.

NCT ID: NCT05883852 Recruiting - Clinical trials for HER2 Positive Early Breast Cancer

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

Start date: June 7, 2023
Phase: Phase 3
Study type: Interventional

compare the efficacy and safety of TCbHP and EC-THP regimen in HER2-positive breast cancer patients

NCT ID: NCT05883670 Recruiting - Cervical Cancer Clinical Trials

Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer

Start date: March 9, 2023
Phase:
Study type: Observational

This study is a Prospective, Multicenter, non-interventive Real-world Study to evaluate the efficacy and safety of the treatment of Serplulimab in patients with Advanced,Recurrent and Metastatic Cervical Cancer. Approximately 118 eligible subjects are planned to be enrolled across all sites.

NCT ID: NCT05883293 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Clinical Study of Allogeneic Adipovarian Active Protein in the Treatment of Severe Idiopathic Pulmonary Fibrosis

CEFFE-IPF
Start date: June 1, 2023
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trail is to study the efficacy and safety of allogeneic adipocyclical active protein in the treatment of severe idiopathic pulmonary fibrosis. The main questions it aims to answer are: 1. Efficacy of allogeneic adipromic active protein in the treatment of severe idiopathic pulmonary fibrosis 2. Safety of allogeneic adipovularic active protein in the treatment of severe idiopathic pulmonary fibrosis. A total of 7 participants will be enrolled. Participants will be asked that they will receive 2ml of each nebulized inhalation Cell Free Fat Extract (CEFFE), inhaled every 3 days, for a total of 7 nebulized inhalation treatments. The clinical trial was designed using a single-center, self-controlled trial with no control group and no blinding.

NCT ID: NCT05883085 Recruiting - Pheochromocytoma Clinical Trials

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effectiveness of anlotinib hydrochloride in the neoadjuvant therapy of locally advanced, or unresectable pheochromocytoma or paragangliom(PPGL). Anrotinib is used preoperatively in order to change unresectable tumors to resectable and reduce the high risk of surgery.

NCT ID: NCT05883059 Recruiting - Stroke Clinical Trials

Clinical Study On Lower Limb Robot For Lower Limb Dysfunction After Stroke

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about effect of lower robot in stroke population. The main question[s] it aims to answer are: the efficacy of lower limb robot assisted training in improving walking ability, lower limb function, cognition, and quality of life in stroke patients.The robot group of patients received lower limb robot assisted training combined with routine rehabilitation treatment. The control group only received routine rehabilitation treatment.Compare two groups to explore the therapeutic effect of lower limb robots on lower limb dysfunction after stroke.